Literature DB >> 2114827

[Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice].

Y Yamada1, H Saito, S Oie, T Takechi, K Nakano, S Takeda.   

Abstract

The effect of combined treatment of UFT with CDDP, especially the optimal time-dependent administration sequence, was studied in nude mice bearing nine human cancer xenografts derived from stomach, colon, lung, breast and uterocervical cancers following treatment with clinically equivalent doses and routes of administration. This combination treatment produced a higher response rate than a single treatment in 7 out of 9 cancers (78%). However, the combination timing of UFT and CDDP was assumed to be an important factor to produce a good therapeutic effect, since the combination effect was different by changing the treatment procedure, e.g., UFT followed by CDDP or CDDP followed by UFT. There was a low correlation between combination effect and the treatment procedure, origin of tissues, histology and doubling time of cancer cells or efficacy of a single agent. The strongest antitumor effect was observed by the treatment with UFT administered both prior to CDDP and after CDDP. Such treatment procedure seemed to be reasonable for cancers of unknown origin or character.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114827

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

Review 1.  The role of tegafur/uracil in pulmonary malignancy.

Authors:  C J Langer
Journal:  Drugs       Date:  1999       Impact factor: 9.546

2.  Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Yasushi Ono; Mitsunori Hino; Yuka Ueda; Ryoko Kamizuru; Masatoshi Omata; Takashi Uehara; Yosuke Tanaka; Tomoyuki Soma; Shoji Kudoh
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.

Authors:  W Koizumi; S Tanabe; K Saigenji; A Ohtsu; N Boku; F Nagashima; K Shirao; Y Matsumura; M Gotoh
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.